Although the optimal IgG scaffold for antibodies targeting PDL1 is still being debated, it is possible that the current PDL1 therapeutic mAbs may not optimally harness FcγR pathways and enhanced ADCC could provide additional therapeutic potential by promoting potent and selective tumor killing (Chen et al. 2020; Jin et al. 2021; Cohen Saban et al. 2023). Here, FCGR2A is linked to neoplasm.